Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.49 |
| ▸ | CA2 | P00918 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084720 | 1.00 | LMNA (0.50) | LMNACA1CA2MAPTCYP2D6 | |
| SCHEMBL7274648 | 0.93 | LMNA (0.48) | LMNACA1CA2MAPTCYP2D6 | |
| SCHEMBL28847759 | 0.93 | LMNA (0.48) | LMNACA1CA2MAPTCYP2D6 | |
| SCHEMBL28847755 | 0.92 | LMNA (0.47) | LMNACA1CA2MAPTCYP2D6 | |
| SCHEMBL11688967 | 0.91 | LMNA (0.46) | LMNACA1CA2MAPTALDH1A1 | |
| SCHEMBL1245994 | 0.91 | LMNA (0.50) | LMNACA1CA2MAPTCYP2D6 | |
| SCHEMBL6896823 | 0.91 | LMNA (0.50) | LMNACA1CA2MAPTCYP2D6 | |
| SCHEMBL4511022 | 0.90 | LMNA (0.52) | LMNACA1CA2MAPTCYP2D6 | |
| SCHEMBL4692008 | 0.88 | LMNA (0.60) | LMNACA1CA2MAPTCYP2D6 | |
| SCHEMBL29028871 | 0.88 | LMNA (0.51) | LMNACA1CA2MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109612-B1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | disclosed |
| US-7799781-B2 | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| EP-2109612-A2 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | AstraZeneca AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| WO-2008093075-A2 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | HSP90AA1, HSP90AB1, HSP90AB2P | LMNA 4400/4885CA1 2719/4885CA2 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.